Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
PharmaNeuroBoost NV (PNB) reported today that both the U.S. Patent and Trade Office (USPTO) and Japanese Patent Office (JPT) granted the patent application of its lead product PNB01, a fixed dose combination of citalopram and low dose pipamperone, as a pharmaceutical composition of matter, for treating a mood disorder or an anxiety disorder.
“Having patents already granted in Europe and Canada, PNB01 now enjoys nearly global patent protection”, says the inventor and CEO Erik Buntinx, psychiatrist, who was first to identify and report the beneficial clinical effects of PNB01 in patients suffering from a Major Depressive Disorder (MDD)”.
PNB already reported the promising clinical trial data obtained with PNB01 over standard of care citalopram from a Phase II Proof of Concept trial in patients with moderate to severe MDD.
“Reaching this key milestone in addition to having received supportive regulatory feedback on its planned Phase III program and the recent closing of EUR 15 M additional funding from its current investors, enables PNB to start up its late stage Phase III development program of PNB01”, says Chief Development Officer Remi Van Den Broeck, MD, MSc “
“When confirmed in Phase III, this novel treatment will be a breakthrough for physicians and patients who are in need for a faster and sustained treatment of MDD, a devastating disorder”, concludes Dr. Erik Buntinx.
PNB01 is the first of two front-running proprietary projects of PNB.
founded in 2006, PNB is a privately held biopharmaceutical company located in Belgium, dedicated to develop best in class CNS therapeutics, based on solid intellectual property. The company’s primary goal is to significantly improve current therapy targeted against mood, anxiety, and psychotic disorders. The two front-running clinical stage proprietary projects (PNB01 and PNB02) are targeted against major depression and schizophrenia, respectively.
PNB01 is the combination of citalopram and a low dose of pipamperone. Citalopram is a well-established antidepressant of the Selective Serotonin Reuptake Inhibitors (SSRI) class. Pipamperone is a well established mild neuroleptic agent that has been used extensively in some European countries for many years.
Source: PharmaNeuroBoost
Tags: regulatory
Bookmark this:
